Gadgets CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell TherapyHealthradar13. Februar 2026 AlloHeme Identified Cancer Relapse Earlier Than Standard Monitoring Methods in AML and MDS Patients Following Allogeneic HCT Ultra‑Sensitive, Non‑Invasive Surveillance…
